Pipeline — Eilean Therapeutics

Pipeline

Guarding tumor crossroads: we are developing precision therapies targeting multiple high value oncogenic pathways.

PROGRAM/TARGET	INDICATION	DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3
lomonitinib FLT3/IRAK4	AML
lomonitinib FLT3/IRAK4
lonitoclax BCL2	CLL
lonitoclax BCL2	AML
balomenib Menin	AML
PTPN2 INHIBITOR	IO/SOLID TUMORS
JAK2/V617F INHIBITOR	Polycythemia Vera/Myelofibrosis
MALT1 DEGRADER	B-cell lymphomas, I&I
BTK COVALENT AND REVERSIBLE INHIBITOR	B-cell lymphomas, I&I
Selective Brain Penetrant CDK2 INHIBITOR	SOLID TUMORS
Selective Brain Penetrant CDK4 INHIBITOR	SOLID TUMORS
Orally Bioavailable KRASG12D INHIBITOR	SOLID TUMORS
Brain & lung penetrable reversible pan-EGFR INHIBITOR	SOLID TUMORS
pan-KRAS Molecular Glue	SOLID TUMORS
c-MET	SOLID TUMORS

PROGRAM/TARGET	PTPN2 INHIBITOR
INDICATION	IO/SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	JAK2V617F INHIBITOR
INDICATION	Polycythemia Vera/Myelofibrosis

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	MALT1 DEGRADER
INDICATION	B-cell lymphomas, I&I

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	BTK COVALENT AND REVERSIBLE INHIBITOR
INDICATION	B-cell lymphomas, I&I

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	Selective Brain Penetrant CDK2 INHIBITOR
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	Selective Brain Penetrant CDK4 INHIBITOR
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	Orally Bioavailable KRASG12D INHIBITOR
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	Brain & lung penetrable reversible panEGFR INHIBITOR
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	panKRAS Molecular Glue
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3

PROGRAM/TARGET	c-MET
INDICATION	SOLID TUMORS

DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3